Principal Institutions: Dana Farber Cancer Institute in partnership with the Pacific Pediatric Neuro Oncology Consortium (PNOC). Oncogenic dysregulation of the RAS/RAF/MEK/ERK pathway has been described in a number of diverse malignancies, including low grade gliomas. Furthermore, mutations in BRAF, which occur in both monomeric and dimeric forms, drive the majority of pediatric LGG. Yet, only ten percent of pediatric LGGs possess BRAF V600E mutations, some of which are targetable by current type I inhibitors (dabrafenib, vemurafenib), which bind the activation site of the V600E mutation to prevent downstream signaling. The application of type I inhibitors to the majority of patients whose tumors do not possess V600E mutations was met with disappointment and in many cases deleterious results due to the unexpected acceleration of tumor growth in treated patients – a result brought about by paradoxical ERK activation in a process termed negative cooperativity. Current therapies for this patient group now target the downstream MEK and MTOR signaling molecules but have yielded responses in only a small subset of patients likely due to poor CNS penetration and downstream location. A promising new class of inhibitors, however, targets all mutations of BRAF, including the much more common dimerizing forms of mutant BRAF, as exemplified by the common KIAA1549:BRAF fusion duplication. This class of BRAF inhibitor (called type II) functions via a completely different mechanism of action via stabilization of the BRAF/MEK complex. Our preclinical results supported by our Brain SPORE grant (Project 4; PIs Kieran and Eck) demonstrated that this inhibitor has excellent CNS penetration as demonstrated by scanning MALDI-TOF analysis, is effective on all BRAF point mutations (not just BRAF V600E) as well as all truncated fusion forms of BRAF and that by virtue of the RAF/MEK complex stabilization, prevents the paradoxical activation that occurs with all type I inhibitors currently available. Clinical trials of these drugs in adults have laid the foundation for moving forward with testing in children, thereby positioning us to design the first trial to test such a novel pathway inhibitor for the most common pediatric brain tumor. TAK-580, a type II inhibitor with excellent CNS penetration and documented activity demonstrated in a number of LGG models based on the work done at our institution, is the focus of our upcoming trial. The trial design includes phase 1, 2 and target validation arms, the latter providing the opportunity to verify CNS penetration in patient tumors and evaluate pre- and post-treatment biopsy samples to study pathway inhibition and possible resistance among unresponsive tumors. This drug has the potential to transform treatment for the majority of patients with the most common pediatric tumor, a tumor for which surgery is often not possible and treatment morbidity high.
Categories
Archives
- November 2018
- September 2018
- June 2018
- May 2018
- January 2018
- December 2017
- November 2017
- August 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- November 2015
- September 2015
- August 2015
- June 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- February 2014
- January 2014
- December 2013
- September 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- July 2012
- June 2012
- March 2012
- January 2012
- May 2011
- November 2010
- October 2010
- August 2010
- June 2010
- March 2010
- July 2009
- June 2009
- March 2009
- February 2009
- January 2009
- November 2008
- October 2008
- July 2008
- June 2008
- May 2007
- December 2006
- August 2006
- May 2006
- March 2006
- January 2006
Leave A Comment